Marker Therapeutics Inc. (MRKR)
$1.33
$-0.01
(-0.38%)
As on 01-Sep-2026 11:31EDT
Market cap
$23 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
16,673,127
10 Years Aggregate
CFO
$-143.80 Mln
EBITDA
$-360.00 Mln
Net Profit
$-363.96 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
| -11.1 | 17.3 | -15.6 | 43.1 | -38.2 | -41.8 | -31.1 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
| -52.1 | -43.2 | 106.8 | -71.6 | -34.5 | -49.7 | -48.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
|
1.3 | 22.8 | 2.3 | -8.7 | -85.5 | -60.1 | -- | 2.0 |
| 82.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 256.3 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.8 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.3 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.1 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.0 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.5 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 585.6 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 348.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Marker Therapeutics (MRKR)
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi... antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas. Read more
-
Co-Founder, CEO, President, Treasurer & Director
Dr. Juan F. Vera M.D.
-
Co-Founder, CEO, President, Treasurer & Director
Dr. Juan F. Vera M.D.
-
Headquarters
Houston, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Marker Therapeutics (MRKR)
What is the current share price of Marker Therapeutics Inc (MRKR) Today?
The share price of Marker Therapeutics Inc (MRKR) is $1.33 (NASDAQ) as of 01-Sep-2026 11:31 EDT. Marker Therapeutics Inc (MRKR) has given a return of -38.22% in the last 3 years.
What is the current PB & PE ratio of Marker Therapeutics Inc (MRKR)?
Since, TTM earnings of Marker Therapeutics Inc (MRKR) is negative, P/E ratio is not available.
The P/B ratio of Marker Therapeutics Inc (MRKR) is 2.00 times as on 28-Aug-2026, a 61 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.88 |
1.36 |
2024 |
-2.64 |
1.53 |
2023 |
-5.94 |
3.48 |
2022 |
-0.07 |
0.11 |
2021 |
-0.19 |
0.18 |
What is the 52 Week High and Low of Marker Therapeutics Inc (MRKR)?
The 52-week high and low of Marker Therapeutics Inc (MRKR) are Rs 2.46 and Rs 0.83 as of 01-Sep-2026.
What is the market cap of Marker Therapeutics Inc (MRKR)?
Marker Therapeutics Inc (MRKR) has a market capitalisation of $ 23 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Marker Therapeutics Inc (MRKR)?
Before investing in Marker Therapeutics Inc (MRKR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.